Fairfax, Virginia
Phase 1 cancer trials in Fairfax, VA
148 Phase 1 cancer studies are recruiting participants at sites in Fairfax as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Fairfax at a glance
- 148 studies are recruiting at a site in Fairfax.
- By phase: Phase 1 (69), Phase 1/2 (79).
- By sponsor: industry (145), university, hospital or other (3).
- By research area: Lung Cancer (77), Breast Cancer (53), Prostate Cancer (6), Lymphoma (4), Melanoma (4), Pancreatic Cancer (4).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Fairfax
Basic details from each study's public record (the 30 most recently updated of 148). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- NEXT Oncology - Virginia Cancer Specialists
- Registry record
- NCT06253871 · updated
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study sites
- Inova Schar Cancer Institute · Virginia Cancer Specialists, PC
- Registry record
- NCT06324357 · updated
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Inova Schar Cancer Institute ( Site 0051)
- Registry record
- NCT06686394 · updated
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Inova Schar Cancer Institute Clinical Trials
- Registry record
- NCT07488676 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study sites
- Inova Schar Cancer Institute · NEXT Virginia
- Registry record
- NCT06270706 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT06638307 · updated
A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Prelude Therapeutics Incorporated
- Study site
- NEXT Virginia
- Registry record
- NCT07905001 · updated
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- NEXT Texas LLC - Virginia
- Registry record
- NCT07503808 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Next Oncology
- Registry record
- NCT05315700 · updated
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 19 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT06586957 · updated
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT07029399 · updated
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- USOR Virginia Cancer Specialists
- Registry record
- NCT05579366 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Lung cancer studies recruiting in Fairfax
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- NEXT Virginia
- Registry record
- NCT05786924 · updated
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- LG Chem
- Study site
- NEXT Oncology
- Registry record
- NCT06332755 · updated
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Phase 1/2
- Ages 18 to 75
- All sexes
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
- Study site
- NEXT Virginia
- Registry record
- NCT06385925 · updated
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 to 99
- All sexes
- Sponsor
- Erasca, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT06983743 · updated
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- NEXT Oncology Virginia
- Registry record
- NCT07277413 · updated
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT07730021 · updated
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- NEXT Virginia
- Registry record
- NCT07111520 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Virginia Cancer Specialists, PC
- Registry record
- NCT04886804 · updated
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- NEXT Oncology Virginia
- Registry record
- NCT07080242 · updated
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT07458347 · updated
A KRAS Inhibitor in Participants With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Ensem Therapeutics
- Registry record
- NCT07912593 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07020221 · updated
A Study of DS-3939a in Participants With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- Inova Schar Cancer Institute
- Registry record
- NCT07739966 · updated
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- TRIANA Biomedicines, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT07491497 · updated
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Inova Schar Cancer · Inova Schar Cancer Infusion Pharmacy
- Registry record
- NCT07519655 · updated
A 2-part Phase 1/2 Open-label Trial on ODM-212
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Orion Corporation, Orion Pharma
- Study site
- NEXT Oncology Virginia
- Registry record
- NCT07563738 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Fairfax
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- NEXT Virginia
- Registry record
- NCT05997615 · updated
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Virginia Cancer Specialists PC
- Registry record
- NCT04221542 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Ask about studies near Fairfax
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections